Literature DB >> 34049943

The effect of tezepelumab on airway hyperresponsiveness to mannitol in asthma (UPSTREAM).

Asger Sverrild1, Susanne Hansen2,3, Morten Hvidtfeldt2, Carl-Magnus Clausson4, Olga Cozzolino4, Samuel Cerps4, Lena Uller4, Vibeke Backer5, Jonas Erjefält4, Celeste Porsbjerg2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 34049943     DOI： 10.1183/13993003.01296-2021

Source DB:  PubMed          Journal:  Eur Respir J        ISSN： 0903-1936            Impact factor:   16.671


× No keyword cloud information.
  10 in total

Review 1.  Novel Biological Therapies for Severe Asthma Endotypes.

Authors:  Corrado Pelaia; Giulia Pelaia; Claudia Crimi; Angelantonio Maglio; Anna Agnese Stanziola; Cecilia Calabrese; Rosa Terracciano; Federico Longhini; Alessandro Vatrella
Journal:  Biomedicines       Date:  2022-05-04

Review 2.  Dupilumab and tezepelumab in severe refractory asthma: new opportunities.

Authors:  Beatrice Ragnoli; Jaymin Morjaria; Patrizia Pignatti; Paolo Montuschi; Mariangela Barbieri; Lucrezia Mondini; Luca Ruggero; Liliana Trotta; Mario Malerba
Journal:  Ther Adv Chronic Dis       Date:  2022-05-25       Impact factor: 4.970

Review 3.  Advances and Challenges of Antibody Therapeutics for Severe Bronchial Asthma.

Authors:  Yuko Abe; Yasuhiko Suga; Kiyoharu Fukushima; Hayase Ohata; Takayuki Niitsu; Hiroshi Nabeshima; Yasuharu Nagahama; Hiroshi Kida; Atsushi Kumanogoh
Journal:  Int J Mol Sci       Date:  2021-12-22       Impact factor: 5.923

4.  Missing sputum samples are common in asthma intervention studies and successful collection at follow-up is related to improvement in clinical outcomes.

Authors:  Laurits Frøssing; Morten Hvidtfeldt; Alexander Silberbrandt; Asger Sverrild; Celeste Porsbjerg
Journal:  ERJ Open Res       Date:  2021-02-07

Review 5.  Biologics in Asthma: A Molecular Perspective to Precision Medicine.

Authors:  Brittany Salter; Paige Lacy; Manali Mukherjee
Journal:  Front Pharmacol       Date:  2022-01-19       Impact factor: 5.810

Review 6.  Specific Therapy for T2 Asthma.

Authors:  Diego Bagnasco; Elisa Testino; Stefania Nicola; Laura Melissari; Maria Russo; Rikki Frank Canevari; Luisa Brussino; Giovanni Passalacqua
Journal:  J Pers Med       Date:  2022-04-07

7.  Baseline type 2 biomarker levels and response to tezepelumab in severe asthma.

Authors:  Jonathan Corren; Tuyet-Hang Pham; Esther Garcia Gil; Kinga Sałapa; Pin Ren; Jane R Parnes; Gene Colice; Janet M Griffiths
Journal:  Allergy       Date:  2022-02-09       Impact factor: 14.710

Review 8.  Biologic Therapies in Pediatric Asthma.

Authors:  Evanthia P Perikleous; Paschalis Steiropoulos; Evangelia Nena; Emmanouil Paraskakis
Journal:  J Pers Med       Date:  2022-06-18

Review 9.  Challenges in severe asthma: Do we need new drugs or new biomarkers?

Authors:  Adil Adatia; Harissios Vliagoftis
Journal:  Front Med (Lausanne)       Date:  2022-09-27

10.  House dust mite sensitization and exposure affects bronchial epithelial anti-microbial response to viral stimuli in patients with asthma.

Authors:  Samuel Cerps; Asger Sverrild; Sangeetha Ramu; Juan José Nieto-Fontarigo; Hamid Akbarshahi; Mandy Menzel; Cecilia Andersson; Sofia Tillgren; Morten Hvidtfeldt; Celeste Porsbjerg; Lena Uller
Journal:  Allergy       Date:  2022-02-11       Impact factor: 14.710
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.